MetaCap

Arcus Biosciences Inc. (RCUS)

NYSE: RCUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

15.62-0.16 (-1.01%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RCUS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.64
52-week range
15.56 – 31.74
Day range
15.56 – 16.66
Volume / Avg
1.67M / 1.85M
Beta
—

52-week range

$15.56$31.74

RCUS stock today

Arcus Biosciences (RCUS) closed at $15.62 on Nov 20, down 1.01% (-$0.16), versus the S&P 500's 3.70% decline. Shares are 50.8% below their 52-week high of $31.74, set on Jun 30, 2026 and 0.4% above the 52-week low of $15.56, near the bottom of the past year's range. RCUS is down 34.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 29.2%.

Arcus Biosciences has posted a net loss over the last twelve months (EPS of -$3.64), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Arcus Biosciences

Company profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Terry J. Rosen Ph.D.
Headquarters
Hayward, CA
Employees
601
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Arcus Biosciences generated $247.0 million in revenue, down 4.3% from fiscal 2024, its first annual decline since 2022. Arcus Biosciences reported a net loss of $353.0 million, compared with a loss of $283.0 million a year earlier. Operating margin was -156.3%.

Arcus Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$247.00M$258.00M$117.00M$112.00M$383.00M
Growth-4.26%+120.51%+4.46%-70.76%+391.03%
Net income$-353.00M$-283.00M$-307.00M$-267.00M$53.00M
EPS (diluted)$-3.29$-3.14$-4.15$-3.71$0.71

Analyst forecast

Forecast

Consensus (15 analysts)

strong_buy

Avg. price target

$41.00+162.48%

  • Strong buy 1
  • Buy 12
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $23.00High $50.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-1.27 vs $-0.92
Surprise
-38.04%

RCUS news

All RCUS news

Arcus Biosciences peers

Health Care sector
RCUS peer companies
CompanyPrice% ChgMarket capCompare
HCMHUTCHMED (China) Limited ADR13.22-1.71%$2.30Bvs RCUS
PHVSPharvaris N.V.31.28-1.20%$2.21Bvs RCUS
PRGOPerrigo Company plc15.94-0.62%$2.21Bvs RCUS
NAMSNewAmsterdam Pharma Company N.V.18.41-5.64%$2.21Bvs RCUS
PBHPrestige Consumer Healthcare Inc.49.63+0.06%$2.35Bvs RCUS
LKFTLakefront Biotherapeutics ADR33.31-0.24%$2.18Bvs RCUS
PVLAPalvella Therapeutics Inc.142.85-2.00%$2.09Bvs RCUS
MBXMBX Biosciences Inc.49.55-7.23%$2.46Bvs RCUS

Indexes, lists and sector

Arcus Biosciences stock FAQ

What is Arcus Biosciences's stock price today?

RCUS last traded at $15.62 as of Nov 20, 4:00 PM EST, down 1.01% on the day. Prices are delayed at least 15 minutes.

Who is Arcus Biosciences's CEO?

Dr. Terry J. Rosen Ph.D. is the chief executive officer of Arcus Biosciences Inc., which has about 601 employees.

What is the RCUS 52-week high?

The 52-week high for RCUS is $31.74 and the 52-week low is $15.56. The stock is currently 50.8% below its high.

Compare RCUS